Exhibit 10.1
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED
BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF
PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS
DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”.
CONSULTING AGREEMENT
This consulting agreement (“Agreement”) is made by and between VIRACTA THERAPEUTICS, INC., having a place of business at 2533 South Coast Hwy 101, Suite 210, Cardiff, CA 92007 USA, together with its affiliates (“Company”) and Lisa Rojkjaer, M.D., an individual with a place of business at [***] (“Consultant”), effective on the 5th day of May, 2023 at 4:59pm PDT (one minute before the effective date and time of Consultant’s resignation from her former position as Chief Medical Officer of the Company such that there is no break in service) for the purpose of setting forth the exclusive terms and conditions by which Company will acquire Consultant’s services on a temporary basis.
1. WORK AND PAYMENT. Attached to this Agreement as Exhibit A is a project assignment describing the work Consultant will perform (“Project Assignment”). This Project Assignment, and any future Project Assignment, will be subject to the terms and conditions of this Agreement and will set forth at a minimum the following terms: (a) Consultant’s rate of payment for such work, (b) expenses to be reimbursed in connection with such work (c) the period, schedule and specifications for the Project Assignment, and (d) such other terms and conditions as the parties may agree to. Company is not obligated to issue any additional Project Assignments under this Agreement. Subject to the terms of this Agreement, Consultant will, to the best of her ability and in a satisfactory and workmanship like manner, render the services set forth in Project Assignment(s) by the completion dates set forth therein. In completing the Project Assignments, unless otherwise agreed by Viracta, Consultant agrees to provide her own equipment, tools and other materials at his or her own expense. Consultant may not subcontract or otherwise delegate her obligations under this Agreement without Company’s prior written consent.
2. PROPRIETARY INFORMATION.
2.1 Information Defined. During the term of this Agreement and in the course of Consultant’s performance hereunder, Consultant may receive and otherwise be exposed to confidential and proprietary information of Company relating to Company’s business practices, finances and expenses, customer lists, strategies, designs, technologies and inventions. Such information may include, but is not limited to, documents, prototypes, compounds, samples, formulations, technical data, trade secrets, know-how, research, devices, components, materials, product or business plans, services, customer and collaborator lists, market analyses, software, assays, discoveries, inventions, ideas, techniques, processes, designs, drawings, marketing plans, financial analyses or equipment. Any of this information, in whatever form and whether or not marked as confidential or proprietary, and all derivatives, improvements and enhancements to any of the above, whether provided to Consultant, or created or developed by Consultant under this Agreement, as well as information of third parties as to which Company has an obligation of confidentiality shall all be treated as the confidential and proprietary information of Company (all of the above collectively referred to as “Information”). Notwithstanding anything to the contrary herein, Consultant and Company acknowledge and agree that any information that Consultant can demonstrate by written documentation to have become publicly known without fault on the part of Consultant shall not be deemed to be “Information” hereunder. Information received by Consultant in her previous capacity as the Company’s Chief Medical Officer remains subject to that certain At Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement dated May 12, 2020 (as subsequently amended).
2.2 Restrictions on Use and Disclosure. Consultant acknowledges the confidential and secret character of the Information, and agrees that the Information is the sole, exclusive and extremely valuable property of Company. Accordingly, Consultant agrees not to reproduce any of the Information without the applicable prior written consent of Company, not to use the Information except in the performance of this Agreement, and not to disclose all or any part of the Information in any form to any third party, either during or after the term of this Agreement, without the prior written consent of Company. Upon termination of this Agreement for any reason, including expiration of term, Consultant agrees to cease using and to return to Company all whole and partial copies and derivatives of the Information, whether in Consultant’s possession or under Consultant’s direct or indirect control.
[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.